In a nutshell The study summarized the outcomes of bisphosphonates and RANKL-inhibitors as supportive treatment in men with prostate cancer (PC) and bone metastases (BM). The authors recommended that a balance between the efficacy and safety of such therapies must be considered for preventing skeletal events in such patients. Some background Men whose...
Read More
In a nutshell The aim of this study was to evaluate the safety and effectiveness of combining androgen deprivation therapy (ADT) with docetaxel (Taxotere) plus prednisone (Deltasone) in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The study found that this combination improved the outcomes of these...
Read More
In a nutshell This study assessed whether olaparib (Lynparza) affected progression-free survival (PFS; survival without cancer worsening) in patients with metastatic castration-resistant prostate cancer (mCRPC) and certain genetic mutations (abnormalities). The study found that olaparib improved PFS in these patients. Some...
Read More
In a nutshell This study evaluated the long-term outcomes of docetaxel (Taxotere) plus hormone therapy for patients with metastatic prostate cancer (cancer that spread outside the prostate). This study found that this treatment combination improved survival for these patients, regardless of tumor burden. Some background One treatment for...
Read More
In a nutshell The authors aimed to determine the use of pre-treatment bone scan index (BSI) as a prognostic (predictive) factor in hormone-naïve men with prostate cancer who have bone tumors. The authors concluded that pre-treatment BSI and patients age were independent prognostic factors for men with hormone-naïve prostate cancer with bone...
Read More
In a nutshell This study examined the effects of enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer (mCRPC) that has spread to the lungs and/or liver. Researchers reported that enzalutamide is safe and effective for men with mCRPC affecting the lung or liver. Some background When prostate cancer spreads outside of...
Read More
In a nutshell This study examined the safety and effectiveness of radium-223, alone or in combination with other therapies, in treating metastatic castration-resistant prostate cancer (mCRPC). Researchers concluded that radium-223 was well tolerated and can be safely combined with additional therapies. Combined therapies were associated with improved...
Read More
In a nutshell This review examined the effects of different radiopharmaceuticals in reducing bone pain in advanced prostate cancer. Researchers concluded that radiopharmaceuticals were associated with a significant reduction in bone pain. Some background When prostate cancer spreads outside of the prostate (also called metastatic prostate cancer),...
Read More
In a nutshell This study determined the benefit of combined hormone-chemotherapy in the treatment of metastatic prostate cancer. Researchers concluded that combination therapy resulted in significantly longer overall survival. Some background Androgen deprivation therapy (ADT) is a type of hormone therapy that targets androgens, the male sex...
Read More
